Abstract: Objective： To explore the effect and side effect of three DDPcontaining combined chemotherapy regimens in the treatment of advanced nonsmall cell lung cancer (NSCLC). Methods： One hundred and thirty patients with advanced NSCLC were randomly divided into three groups: the NP group (n=45) was given vinorelbine plus DDP, the GP group (n=43) was given gemcitabine plus DDP and the TP group (n=42) was given docetaxel plus DDP. Results： ① The short-term response rate of groups NP, GP and TP was 42.2%(19/45), 44.2%(19/43) and 47.6%(20/42), respectively. There was no significant difference in the three groups(P＞0.05); ② Leukopenia was more significantly decreased in the GP group than in the NP and TP groups, and thrombocytopenia was more significantly increased in the GP group than in the NP and TP groups(P＜0.05). Phlebitis only occurred in the NP group (P＜0.001). Nausea and vomiting had no significant difference among the three groups(P＞0.05); ③ The median survival period and the 1-year survival rate of the NP, GP and TP groups were 9.8 months, 10.1 months and 10.3 months and 39.13%, 39.97% and 40.25%, respectively. There was no significant difference in the three groups(P＞0.05). Conclusion： DDP combined with vinorelbine, gemcitabine or docetaxel has a definite efficacy for patients with non-small cell lung cancer. The side effects are reversible and easily tolerated. All three regimens can be applied to first line chemotherapy.

Key words: Carcinoma, non-small cell lung, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel